These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36981958)

  • 1. The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series.
    Moroșan E; Popovici V; Elian V; Dărăban AM; Rusu AI; Licu M; Mititelu M; Karampelas O
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Most consumed processed foods by patients on hemodialysis: Alert for phosphate-containing additives and the phosphate-to-protein ratio.
    Watanabe MT; Araujo RM; Vogt BP; Barretti P; Caramori JCT
    Clin Nutr ESPEN; 2016 Aug; 14():37-41. PubMed ID: 28531397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacing Phosphorus-Containing Food Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal Disease Patients: A Randomized Clinical Trial.
    de Fornasari ML; Dos Santos Sens YA
    J Ren Nutr; 2017 Mar; 27(2):97-105. PubMed ID: 27751628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
    Bertonsello-Catto VR; Lucca LJ; da Costa JAC
    Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial.
    Sullivan C; Sayre SS; Leon JB; Machekano R; Love TE; Porter D; Marbury M; Sehgal AR
    JAMA; 2009 Feb; 301(6):629-35. PubMed ID: 19211470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
    Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
    Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
    J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.
    Lopes AA; Tong L; Thumma J; Li Y; Fuller DS; Morgenstern H; Bommer J; Kerr PG; Tentori F; Akiba T; Gillespie BW; Robinson BM; Port FK; Pisoni RL
    Am J Kidney Dis; 2012 Jul; 60(1):90-101. PubMed ID: 22385781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary Phosphate and the Forgotten Kidney Patient: A Critical Need for FDA Regulatory Action.
    Calvo MS; Sherman RA; Uribarri J
    Am J Kidney Dis; 2019 Apr; 73(4):542-551. PubMed ID: 30686528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks.
    Brauer A; Waheed S; Singh T; Maursetter L
    J Ren Nutr; 2019 Mar; 29(2):156-162. PubMed ID: 30087012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
    Gasu V; Ashong M; Seferi A; Fitzpatrick A
    JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary trends and management of hyperphosphatemia among patients with chronic kidney disease: an international survey of renal care professionals.
    Fouque D; Cruz Casal M; Lindley E; Rogers S; Pancířová J; Kernc J; Copley JB
    J Ren Nutr; 2014 Mar; 24(2):110-5. PubMed ID: 24447438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
    Yin J; Yin J; Lian R; Li P; Zheng J
    BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing nutrition and serum phosphorus in maintenance dialysis.
    Fouque D; Horne R; Cozzolino M; Kalantar-Zadeh K
    Am J Kidney Dis; 2014 Jul; 64(1):143-50. PubMed ID: 24819675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.